The race to acquire a chunk of debt-laden Wockhardt’s domestic formulations business is heating up and offers are expected in the final week of November, according to an Indian media report which pushed up shares of the company that makes generic and bio-pharmaceutical formulations, active pharmaceutical ingredients and vaccines.
In the latest development in the loss-making firm’s quest to sell a chunk of itself to reduce its hefty debt,...


